omniture
logo
Search

/DISREGARD RELEASE: HanAll Biopharma and Daewoong Pharmaceutical/

HanAll Biopharma and Daewoong Pharmaceutical
2022-04-12 15:34 1650

We are advised by HanAll Biopharma and Daewoong Pharmaceutical that journalists and other readers should disregard the news release, "Daewoong Pharmaceutical and HanAll Biopharma Invest in Turn Biotechnologies to Expand Growth Initiative", issued 11-Apr-2022 over PR Newswire.

Source: HanAll Biopharma and Daewoong Pharmaceutical
Related Stocks:
Korea:069620
Media Room more

Daewoong Pharmaceutical Captivates Global Experts at AMWC-SEA with 'Nabolift,' Redefining Toxin Treatments

2024-12-05 16:33
1501
On November 20, medical professionals attending the 'Nabota Master Class (NMC)' held in Bangkok, Thailand, posed for a commemorative photo.

Daewoong Pharmaceutical Unveils 'Innovative Drug Delivery Technologies' in Milan--From World's First Microneedle Therapy to Once-a-Month Obesity Treatment

2024-10-10 06:16
1685

Daewoong Pharmaceutical Receives Positive Recommendation from IDMC to Continue Developing its First-in-Class PRS Inhibitor, Bersiporocin

2024-07-29 20:00
1819

Novosis Putty Sets the Stage for U.S. Market Success with Promising Clinical Results

2024-05-14 20:00
1770

Daewoong Pharmaceutical Received GMP Certification from Brazilian ANVISA

2023-11-28 08:00
1667

Daewoong Pharmaceutical Initiates Global Export of 'Novel Drug' Launching 'Fexuprazan' in the Philippines

2023-08-16 13:00
2690
Daewoong Pharmaceutical Initiates Global Export of 'Novel Drug' Launching 'Fexuprazan' in the Philippines
Related News

YolTech Therapeutics Announces Successful Completion of Dose Escalation Phase in Phase I Trial of YOLT-201 for ATTR

2024-12-21 16:23
2446

United Imaging Intelligence at RSNA 2024: Empowering a More Intelligent and Connected World with Medical AI

2024-12-20 22:00
1041

Medicilon Appoints Dr. Lilly Xu as Chief Technology Officer

2024-12-20 21:30
930
Dr. Lilly Xu

Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration

2024-12-20 20:20
3086

PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular Lymphoma

2024-12-19 23:00
1378

Corvia Medical Achieves CE Certification for Atrial Shunt Under New EU MDR Standards

2024-12-21 04:03
1276
collection